Investors

Corporate information

Our history is the sum of the efforts, dreams, and vision of a group of entrepreneurs, businessmen and experts who bet on the medical Cannabis industry in Colombia, to contribute to local and regional development while attaining a prominent place in the global industry.

Today, medcann Pharma Inc. is a Canadian holding company with an established presence in Colombia and newer subsidiaries in Spain and Peru, that focuses its efforts through our strategy of the development of novel cannabis genetics for medical and scientific purposes under our Corporate Governance Code, and the highest standards of Compliance.

It is our purpose to contribute in an innovative, responsible, and sustainable way to the global progress of the medical cannabis industry, through collaborative work with the medical and scientific community, patients, governments, academia, and technology partners, with the trust and support of our investors.

Read our leaders´ latest  interview with Global Cannabis Intelligence: The Future of Global Cannabis Genetics and Seeds Supply with medcann Pharma.

The interview

A glance to the industry and the main reasons to invest in Colombia and in medcann Pharma:

  • US$ 62.7b, the global medical cannabis market
    forecast by 2024.
  • Latin America and the Caribbean (LAC) is the second larger region in the world - after USA - for cannabis projects global investment.
  • Colombia has attracted most of foreign investment commitments in LAC.
  • The country has a cost-effective production with an export share representing over 25% of the total cannabis to be traded worldwide.
  • Colombian legislation represents an important business opportunity worldwide for cannabis genetics and seeds, as it is one of the most advanced in terms of genetic Intellectual Property (IP).
  • Colombia is part of the selected group of countries with a legal genetic sourcing.

  • Download presentation

Study on the economic impact of the medical Cannabis industry in Colombia, developed by EConcept and sponsored by medcann Pharma in 2019. Calculated estimates if the sector develops as expect and with the required speed:

icon

Colombia has an exceptional opportunity to increase exports weight in the GDP and diversify them with a new product such as cannabis for medical use.

icon

The country could reach exports up to US$ 17,700 million with a minimum value of US$ 1,146 million and an average of US$ 5,918 million.

icon

The industry could boost the national labor market with more than 21,000 new jobs on average, exceeding up to 100,000 in the most optimistic scenario.

Download study
(Available in Spanish)

Contact information

Corporate Communications and Press Media

Ana María Prieto

Communications Manager

ana.prieto@medcann.com.co